Psoriasis : Pathogenesis, Assessment, and Therapeutic Update - 22/05/16
Doi : 10.1016/j.cpm.2016.02.004
Stephen M. Schleicher, MD a, b, c, d, ⁎ 
a DermDOX Center for Dermatology, 20 North Laurel Street, Hazleton, PA 18201, USA
b St. Luke’s Health Systems, 801 Ostrum Street, Bethlehem, PA 18015, USA
c The Commonwealth Medical College, Scranton, PA 18605, USA
d University of Pennsylvania Medical College, Philadelphia, PA 19104, USA
∗DermDOX Center for Dermatology, 20 North Laurel Street, Hazleton, PA 18201.DermDOX Center for Dermatology20 North Laurel StreetHazletonPA18201
Résumé |
Psoriasis is a chronic condition that affects more than 7 million Americans. This article explores the pathogenesis and physical signs of psoriasis. Over the past 2 decades enhanced understanding of the immunologic basis of psoriasis has led to the development of new systemic agents that have revolutionized the management of this disease, and these modalities, along with traditional therapies, are described.
Le texte complet de cet article est disponible en PDF.Keywords : Psoriasis, Biologics, Psoriatic comorbidities, Psoriatic arthritis
Plan
| Financial Disclosure: Dr S.M. Schleicher is a speaker for Aqua Pharmaceuticals and Celgene and has served as a Principal Investigator for Amgen, Exeltis, Galderma, Genentech, Regeneron, and Taro. |
© 2016
Elsevier Inc. Tous droits réservés.
Vol 33 - N° 3
P. 355-366 - juillet 2016 Retour au numéro
Article précédent
- The Human Papillomavirus and Its Role in Plantar Warts : A Comprehensive Review of Diagnosis and Management
- Tracey C. Vlahovic, M. Tariq Khan
- Dermatologic Concerns of the Lower Extremity in the Pediatric Patient
- Tracey C. Vlahovic
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?